. We identi®ed a cell line (Ex187) carrying an insertion in LRP6 by direct sequencing of complementary DNAs obtained by 59 rapid ampli®cation of cDNA ends (RACE) 22 . Germline chimaeras generated by blastocyst injection were test bred and backcrossed to C57/BL6 mice for four generations before setting up intercrosses of heterozygous mutant animals. To genotype animals at weaning, dot blots of DNA prepared from tail biopsies were probed with vector (bgeo) sequences 23 . Mutant embryos before 8.5 d.p.c. were genotyped by the X-gal staining 4 intensity of yolk sacs. Mutant embryos at later stages were identi®ed by morphology or X-gal staining. Murine embryonic ®broblasts were isolated from eviscerated 12.5-and 14.5-d.p.c. embryos using standard procedures 24 and were genotyped by X-gal staining intensity. Northern blot analysis of midgestation embryos and ®broblasts was used to provide independent con®rmation of genotypes scored by X-gal staining. Probes: LRP6, a 1.9-kbp BglII cDNA fragment (39 of the insertion); LRP5, a 400-bp EcoRI/NotI cDNA fragment containing the 39 untranslated region (mouse expressed sequence tag, Genebank no. AI119858); b-actin, 610-bp PstI cDNA fragment.
Skeletal preparation and general histology
We carried out skeletal preparations by standard methods 12 . For histology of tissue sections, embryos were ®xed in Bouin's solution for 5±12 h (depending on size of embryo), dehydrated and embedded in paraf®n, and 8-mm sections were stained with haematoxylin and eosin according to standard protocols.
vt;LRP6 matings vt/vt mice (Jackson Laboratories, stock no. 000553) were crossed with LRP6 heterozygotes to produce vt/+;LRP6 -/+ and vt/+;+/+ offspring. Compound heterozygotes were subsequently mated to vt homozygotes. Inheritance of the LRP6 mutant allele was determined by b-gal staining of yolk sacs or dot blots of tail DNA as described above.
In situ hybridization
Whole-mount in situ hybridization of mouse embryos was carried out essentially as described 25 . Whole-mount embryos were sectioned on a cryostat. Probes were provided by A. McMahon (Pax3, Wnt-3a, Wnt-1 and Shh), G. Martin (Fgf8) and R. Harland Oestrogen produces diverse biological effects through binding to the oestrogen receptor (ER) 1 . The ER is a steroid hormone nuclear receptor, which, when bound to oestrogen, modulates the transcriptional activity of target genes 2 . Controversy exists, however, concerning whether ER has a role outside the nucleus 3 , particularly in mediating the cardiovascular protective effects of oestrogen 4 . Here we show that the ER isoform, ERa, binds in a ligand-dependent manner to the p85a regulatory subunit of phosphatidylinositol-3-OH kinase (PI(3)K). Stimulation with oestrogen increases ERa-associated PI(3)K activity, leading to the activation of protein kinase B/Akt and endothelial nitric oxide synthase (eNOS). Recruitment and activation of PI(3)K by ligandbound ERa are independent of gene transcription, do not involve phosphotyrosine adapter molecules or src-homology domains of p85a, and extend to other steroid hormone receptors. Mice treated with oestrogen show increased eNOS activity and decreased vascular leukocyte accumulation after ischaemia and reperfusion injury. This vascular protective effect of oestrogen was abolished in the presence of PI(3)K or eNOS inhibitors. Our ®ndings de®ne a physiologically important non-nuclear oestrogen-signalling pathway involving the direct interaction of ERa with PI(3)K.
PI(3)K mediates the cellular effects of platelet-derived growth factor (PDGF) 5 , insulin 6 and vascular endothelial growth factor (VEGF) 7 . The predominant form of PI(3)K comprises p85a, an adapter/regulatory subunit of relative molecular mass 85,000 (M r 85K), and p110, a catalytic subunit 8 of M r 110K. PI(3)K catalyses the formation of lipid mediators 9,10 which recruit signalling molecules containing phosphatidylinositol (PtdIns)-3,4,5-P 3 -binding or pleckstrin homology domains such as phosphatidylinositol-dependent kinases and protein kinase Akt 11, 12 . 14 , inactivation of glycogen synthase kinase-3 (ref. 15) , and activation of eNOS 16, 17 and cell survival pathways 18 . Although oestrogen stimulates eNOS activity 19 and promotes cell survival, it is not known whether PI(3)K mediates these effects of oestrogen.
In human vascular endothelial cells, physiological concentrations of 17b-oestradiol (E 2 ) increased eNOS activity in a biphasic manner (effector concentration for half-maximal response (EC 50 ) < 0.1 nM) (Fig. 1a, b) . The initial increase was mediated by mitogen-activated protein (MAP) kinases 19 ; the second increase was completely blocked by the PI(3)K inhibitor, wortmannin. The increase in eNOS activity was also blocked by the ER antagonist ICI 182,780; and the inactive E 2 stereoisomer 17a-oestradiol (aE 2 ) had no effect. In murine ®broblasts transfected with ERa and eNOS complementary DNAs, E 2 produced an eightfold increase in eNOS activity in wild-type but not in p85a-de®cient (p85a -/-) ®bro-blasts 20 ( Fig. 1c) . Furthermore, in p85a -/-®broblasts co-transfection of p85a cDNA led to a fourfold increase in E 2 -stimulated eNOS activity, whereas in wild-type ®broblasts co-transfection of a dominant-negative p85a mutant cDNA decreased E 2 -stimulated eNOS activity by more than 50%.
In non-transfected human endothelial cells, E 2 increased endogenous PtdIns-3,4,5-P 3 levels in a time-delayed manner similar to the wortmannin-sensitive phase of eNOS activation (Fig. 2a) . In contrast, insulin rapidly increased endogenous PtdIns-3,4,5-P 3 levels 6 and eNOS activity 21 . Increases in PtdIns-3,4,5-P 3 levels correlated temporally with the ligand-dependent increases in ERa-associated PI(3)K activity (Fig. 2b) ; events that were blocked by ICI 182,780 and wortmannin (Fig. 2c) . Consistent with a rapid, non-nuclear effect of ER on eNOS activation, E 2 -stimulated PI(3)K activity was blocked by another ER antagonist, tamoxifen, but not by the MAP kinase inhibitor PD 98059, or by the transcriptional inhibitor actinomycin D (Fig. 2d) . Insulin, which uses the phosphotyrosine (p-Tyr) adapter molecule, insulin receptor substrate (IRS)-1, to interact with PI(3)K, increased PI(3)K activity in the pTyr and IRS-1 immunoprecipitate (Fig. 2e) , but did not increase or augment E 2 -associated PI(3)K activity. In contrast, E 2 did not increase p-Tyr-or IRS-1-associated PI(3)K activity (Fig. 2e) . These ®ndings suggest that ERa does not recruit PI(3)K that has been already activated by insulin, and that PI(3)K activation by ER and IRS-1 occurs through different mechanisms. Notably, the activation of PI(3)K extended to other steroid hormone nuclear receptors such as the thyroid hormone and glucocorticoid receptors (Fig. 2f) . These interactions may explain some of the previously unrecognized functions of these nuclear hormone receptors.
ERa interacted with p85a in a ligand-dependent manner in both non-transfected endothelial cells (Fig. 3a) and p85a
-/-®broblasts -prostaglandin J 2 (PGJ 2 , 100 mM) on PI(3)K activity in the corresponding steroid hormone nuclear receptor immunoprecipitates.
transfected with ERa and p85a cDNAs (Fig. 3b) . This liganddependent interaction was blocked by ICI 182,780 and was absent in p85a -/-®broblasts transfected with ERa cDNA alone. However, the ER isoform ERb, which is thought to mediate some of the cardiovascular effects of oestrogen 4 , did not interact with p85a or recruit PI(3)K activity after E 2 stimulation (see Supplementary  Information) . The interaction of ERa and p85a also occurred in the absence of adapter molecules or accessory proteins, as human recombinant ERa could still interact with glutathione S-transferase (GST)±p85a fusion protein in a ligand-dependent manner in a cellfree system (Fig. 3c) . This interaction, however, does not involve the src-homology SH2/SH3 domains of p85a (Fig. 3d) which interact with p-Tyr residues of growth hormone receptors and adapter molecules 22, 23 . Heat shock protein 90, which binds and facilitates the function of ER 24 and eNOS 25 , inhibited the interaction of ERa and p85a.
The generation of PtdIns-3,4,5-P 3 leads to the recruitment and activation of Akt 11, 26 . E 2 stimulated Akt kinase activity in a timedelayed manner (Fig. 3e) , similar to the increases observed in PtdIns-3,4,5-P 3 levels and eNOS activity. To determine whether E 2 -stimulated eNOS activation is mediated by Akt, we transiently transfected bovine aortic endothelial cells with adenoviruses containing constitutively active (myr) and dominant-negative (dn) Akt mutants 27 . Transfection of these cells with myr-Akt produced a substantial increase in eNOS activity, whereas overexpression of dnAkt decreased basal eNOS activity below baseline and completely abolished E 2 -stimulated eNOS activity (Fig. 3f) .
To determine the physiological signi®cance of this pathway, we used an established model of ischaemia and reperfusion (I/R) injury in the mouse cremaster muscle 28 . I/R leads to leukocyte recruitment to the vascular wall, an event attenuated by NO and exacerbated by eNOS inhibitors such as L-nitroarginine methylester (L-NAME) 29 . I/R reduced median leukocyte rolling velocity by 13.8 mm s -1 (P , 0.003) and induced a 2.2-fold increase in the number of adherent leukocytes (P , 0.001) (Fig. 4a, b) . Treatment with E 2 increased eNOS activity 3.2-fold and prevented the subsequent changes in leukocyte accumulation and rolling velocity after I/R. When wortmannin or L-NAME was applied to the cremaster muscle, measurements of leukocyte rolling velocity and accumulation were not different between untreated and E 2 -treated mice after I/R, although L-NAME decreased eNOS activity below that of untreated mice (Fig. 4a±c) . These ®ndings indicate that the NOinduced vascular protective effect of oestrogen is predominantly mediated by PI(3)K.
Although the nuclear function of ER is clearly established, previous studies regarding the membrane and cytoplasmic effects of oestrogen remain inconclusive 3 . Linking the ER to PI(3)K suggests that the ER may be involved in a critical function outside the nucleus. In addition, the potential biological effects of oestrogen are considerably broadened because PI(3)K is known to mediate various cellular functions 18 . Although most of the ER is localized to the nucleus, we found that there is an increased level of membrane and cytoplasmic ER after E 2 stimulation (data not shown). Indeed, a study has suggested that membrane-associated ER is involved in mediating NO release from endothelial cells 30 . Thus, it is likely that PI(3)K is being recruited and activated by a small subset of ligandbound, membrane-associated ERs. It remains to be determined, however, whether oestrogen can also activate PI(3)K indirectly, and whether PI(3)K can account for other rapid, non-nuclear effects of oestrogen. Further studies characterizing the interaction domains of ERa and p85a should help clarify these issues.
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Methods
Cell cultures
Human and bovine aortic endothelial cells were obtained enzymatically with Type IA collagenase (1 mg ml -1 ). They were cultured and stimulated under serum-starved conditions consisting of phenol-red-free Medium 199 (Gibco BRL, Life Technologies) with 0.4% charcoal-stripped fetal calf serum.
Immunoprecipitations
Cells were washed with ice-cold PBS and lysed with the following buffer: Tris-HCl (20 mM, pH 7.4), EDTA (10 mM), NaCl (100 mM), IGEPAL (1%), Na 3 VO 4 (1 mM), NaF (50 mM), PMSF (0.1 mg ml -1 ) and aprotinin (0.3 mg ml -1
). We added the immunoprecipitating antibody (1 mg) to equal amounts of cell lysates (0.5±1 mg) in 500 ml of lysis buffer for 1 h at 4 8C with gentle rocking. Afterwards, 40 ml of 1:1 Protein-A-agarose was added and the entire mixture was rocked gently for another 1 h at 4 8C. The mixture was then centrifuged at 12,000g for 5 min at 4 8C. The supernatant was removed and the immunoprecipitate was washed three times with 500 ml of washing buffer, which differs from the lysis buffer in having 150 mM NaCl instead of 100 mM NaCl. We then separated proteins in the washed immunoprecipitate by SDS-PAGE and immunoblotted them with anti-ERa (Ab-10: Clone TE111.5D11, NeoMarkers, Fremont, CA) or anti-p85a (Upstate Biotech., Lake Placid, NY) antibody.
GST fusion protein-af®nity puri®cation
Human recombinant GST±p85a fusion protein or GST (Sigma) bound to glutathioneagarose beads (1 mg protein per 20 ml beads) was suspended in 400 ml of Escherichia coli protein extract solution (10 mg ml -1 ) and incubated with 1 mg human recombinant ERa (Panvera, Madison, WI) for 1 h at 4 8C. We pelleted the samples, and washed the beads ®ve times with a buffer containing 50 mM potassium phosphate, pH 7.5, 150 mM KCl, 1 mM MgCl 2 , 10 % (v/v) glycerol and 1% (v/v) Triton X-100 plus protease inhibitors. The beads were re-suspended in 50 ml of 2´Laemmli's buffer and boiled for 5 min. Proteins were separated on SDS-PAGE.
Model of vascular injury
Ten-week-old, 24 g, male C57BL/6 mice (Hilltop, Scottsdale, PA) were subcutaneously implanted with 1.5 mg of slow-release E 2 tablets (Innovative Research of America, Sarasota, FL) 3±5 days before experiments to ensure steady-state serum E 2 levels and to avoid any effects of surgery on baseline haemodynamic parameters. Mice implanted with E 2 tablets had a serum E 2 level of 760 6 30 pg ml -1 compared with that of vehicle-treated mice (24 6 6 pg ml -1 ). Mice were anaesthetized and the cremaster muscle was studied under intravital microscopy 28 . Ischaemia was induced by applying pressure to supplying arteries just suf®cient to stop blood¯ow for 30 min. In some experiments, wortmannin (100 nM) or L-NAME (0.1 mM) was applied to the cremaster muscle during the ischaemic period. The pressure was released for reperfusion, and the same vessels were recorded in each animal before and after I/R. The rolling velocities of 25 leukocytes were measured in each venule, sorted and averaged for each rank to construct cumulative histograms. The velocities of 3,750 leukocytes were measured in 150 venules before and after I/R. The number of ®rmly adherent leukocytes was measured before and after I/R in the same 200-mm long segments of venules. The following number of venules were studied for leukocyte adhesion: untreated, 15 venules; E 2 -treated, 20 venules; E 2 -treated with wortmannin, 25 venules; E 2 -treated with L-NAME, 15 venules. Cremaster eNOS activity was measured in three untreated, four E 2 -treated, ®ve E 2 -treated with wortmannin and four E 2 -treated with L-NAME mice.
